Home / Publication / A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

論文

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

Author(s): Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J. Richard Trout, Richard D. Huhn, Michele Gargano, Myra L. Patchen, Richard Walsh, My My Trinh, Mariève Dupuis, Folker Schneller

Year: 2018年2月27日

How Model-informed drug development rescue projects from a risky situation

事例紹介

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

論文

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

ウェビナー

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

ウェビナー

Powered by Translations.com GlobalLink Web Software

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

How Model-informed drug development rescue projects from a risky situation

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

A Randomized, Controlled Trial Evaluating the Efficacy and Safety of BTH1677 in Combination with Bevacizumab, Carboplatin, and Paclitaxel in First-line Treatment of Advanced Non-small Cell Lung Cancer

How Model-informed drug development rescue projects from a risky situation​

Critical Roles for Modeling and Simulation and Real-World Evidence to Inform Challenges in Clinical Trial Diversity Planning

From Data to Decisions: Real-World Impact of Model-Based Meta-Analysis (MBMA) with GSK and Certara

Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis

メルマガ登録

クイックアクセス

ソリューション

お問合せ

How Model-informed drug development rescue projects from a risky situation